Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

January 20, 2026

Conditions
Endometrial AdenocarcinomaEndometrial HyperplasiaFertility PreservationConservative Treatment Therapy
Interventions
PROCEDURE

Hysteroscopic Resection and Hormonal Therapy

Patients underwent hysteroscopic resection of atypical endometrial hyperplasia (AEH) or grade 1-2 endometrial adenocarcinoma (EAC) using a 15 Fr mini-resectoscope. Depending on the case, the procedure included visual D\&C or a combined technique. At the end of the procedure, a 52 mg levonorgestrel-releasing intrauterine device (LNG-IUD) was inserted. In patients with EAC G2 or poor prognostic markers (e.g., MMR deficiency), oral progestin therapy with Megestrol Acetate (160 mg daily) was added. Follow-up included hysteroscopic endometrial biopsy at 3, 6, and 12 months to assess response.

Trial Locations (1)

Unknown

RECRUITING

Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT07077876 - Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment | Biotech Hunter | Biotech Hunter